Long-term trends in incidence and survival of penile cancer in France

Publication date: October 2017
Source:Cancer Epidemiology, Volume 50, Part A
Author(s): Laetitia Daubisse-Marliac, Marc Colonna, Brigitte Trétarre, Gautier Defossez, Florence Molinié, Karine Jéhannin-Ligier, Emilie Marrer, Pascale Grosclaude
BackgroundPenile cancer is rare, and few population-based studies have described changes in time trend. This study aims to determine whether there has been an evolution in incidence and survival of penile cancer over time in France.MethodsRates of age world-standardized incidence (ASRW) and net survival (NS) between 1989 and 2011 were calculated using data from 16 French cancer registries. Time trend incidence and survival analysis were confined to the eight registries operating throughout the full period. Log-linear Poisson regression analysis was used to estimate the average annual percentage change (AAPC) in incidence rates. The incidence rate for the most recent period was also calculated from all 16 cancer registries operating during 2009–2011. Human papillomavirus (HPV) exposure was deduced from the morphological code. NS was estimated using the Pohar–Perme estimator of the net cumulative rate.ResultsNo significant change in incidence was observed between 1989 and 2011 (AAPC: 0.08%; 95%CI: −1.01%; +1.17%). The incidence increased with age. The ASRW in 16 registries operating in 2009–2011 was 0.59 per 100,000 (95%CI: 0.50–0.68). The proportion of cases potentially linked to HPV was nearly 11% and did not change significantly over time. NS decreased with age but did not change over time (around 65% at 5 years).ConclusionPenile cancer remains rare in France, but survival is still low − probably because of delays in diagnosis and limited improvements in care. International clinical trials are needed to develop care recommendations based on an adequate level of evidence.



from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2wOLOlU